-
Mashup Score: 3Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma - 4 day(s) ago
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al looked at the use of belzutifan and outcomes in patients with von Hippel–Lindau disease-asso…
Source: ascopost.comCategories: General Medicine NewsTweet
Extended follow-up of belzutifan in VHL-associated RCC shared at #ASCO2025 highlights sustained outcomes in long-term use. 🔗 https://t.co/F4c18MLLfG #OncologyResearch #KidneyCancer https://t.co/RKDDPXQCjZ